|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Kilotumumab in combination with epirubicin,cisplatin,and capecitabine as first-line treatmetn for gas-tric or oesophagogastric junction adenocarcinoma:An openlabel,dose de-escalation phase 1 b study and a double blind,randomized phase 2 study显示文摘 | lveson T Donehower RC Davidenko I | 2014 | Lancet Oncol2014，15，9： | 1 |
| 2 | Phase II1 , randomized, double-blind, mnlticenter, placebo (P)- controlled trial of Rilotumumab (R) plus Epirubicin, Cisplatin and C apecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study显示文摘 | Cunningham D Tebbutt NC Davidenko I | 2015 | J Clin Oncol (Meeting Abstracts)2015，33，15： | 1 |
| 3 | Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck(SPECTRUM):an open-label phase 3 randomisedtria显示文摘 | Vermorken JB Sthlmacher-Williams J Davidenko I | 2013 | Lancet Oncol2013，14，8： | 1 |
| 4 | Cisplatin and fluorouracil with or without panitumumab in pa- tients with recurrent or metastatic squamouscell carcinoma of the head and neck(SPECTRUM) :an open-label phase 3 ran- domised trial显示文摘 | Vermorken J B St0hlmacher-Williams J Davidenko I | 2013 | Lancet Oncol2013，14，8： | 1 |
| 5 | Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): An open-label phase 3 randomised trial 显示文摘 | Vermorken JB Stohlmacher- Williams J Davidenko I | 2013 | Lancet Oncol2013，14，8： | 1 |
| 6 | Phase 11I, randomized, double-blind, multicenter, placebo (P)- controlled trial of rilotumumab (R) plus epirubicin, cis- platin and capecitabine (ECX) as first-line therapy in pa- tients (pts) with advanced MET-positive (pos) gastric orgastroesophageal junction (G/GEJ) cancer: RILOMET-1 study显示文摘 | Cunningham D Tebbutt NC Davidenko I | 2015 | J Clin Oncol2015，33，： | 1 |
| 7 | Phase llI, randomized, double-blind, muhicenter, placebo (P)- controlled trial of rilotumumab (R) plus epirubicin, cis- platin and capecitabine (ECX) as first-line therapy in pa- tients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study显示文摘 | Cunningham D Tebbutt NC Davidenko I | 2015 | J Clin Oncol2015，33，： | 1 |
| 8 | Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM):an open-label phase 3 randomised trial显示文摘 | Vermorken JB St(o)hlmacher-Williams J Davidenko I | 2013 | Lancet Oncol2013，14，8： | 1 |
| 9 | Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM):an open-label phase 3 randomised trial显示文摘 | Vermorken JB Stohlmacher-Williams J Davidenko I | 2013 | Lancet Oncol2013，14，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员